WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer

被引:75
作者
Kleer, CG
Zhang, YH
Pan, QT
Merajver, SD
机构
[1] Univ Michigan, Ctr Med, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Ctr Med, Dept Pathol, Div Hematol & Oncol, Ann Arbor, MI 48109 USA
来源
NEOPLASIA | 2004年 / 6卷 / 02期
关键词
IGF-binding proteins; MAPK signaling; cell proliferation; cell cycle control; ERK-1/2; phosphorylation;
D O I
10.1593/neo.03316
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inflammatory breast cancer (IBC) is the most lethal form of locally advanced breast cancer. We have found that WISP3 is lost in 80% of human IBC tumors and that it has growth- and angiogenesis-inhibitory functions in breast cancer in vitro and in vivo. WISP3 is a cysteine-rich, putatively secreted protein that belongs to the CCN family. It contains a signal peptide at the N-terminus and four highly conserved motifs. Here, for the first time, we investigate the function of WISP3 protein in relationship to its structural features. We found that WISP3 is secreted into the conditioned media and into the lumens of normal breast ducts. Once secreted, WISP3 was able to decrease, directly or through induction of other molecule(s), the IGF-1-induced activation of the IGF-IR, and two of its main downstream signaling molecules, IRS1 and ERK-1/2, in SUM149 IBC cells. Furthermore, WISP3 containing conditioned media decreased the growth rate of SUM149 cells. This work sheds light into the mechanism of WISP3 function by demonstrating that it is secreted and that, once in the extracellular media, it induces a series of molecular events that leads to modulation of IGF-IR signaling pathways and cellular growth in IBC cells.
引用
收藏
页码:179 / 185
页数:7
相关论文
共 40 条
[1]  
Bartucci M, 2001, CANCER RES, V61, P6747
[2]   The IGF-I receptor in cancer research [J].
Baserga, R .
EXPERIMENTAL CELL RESEARCH, 1999, 253 (01) :1-6
[3]  
Burren CP, 1999, J CLIN ENDOCR METAB, V84, P1096
[4]  
Byrne C, 2000, CANCER RES, V60, P3744
[5]  
ETHIER SP, 1993, CANCER RES, V53, P627
[6]   Insulin-like growth factors and cancer [J].
Fürstenberger, G ;
Senn, HJ .
LANCET ONCOLOGY, 2002, 3 (05) :298-302
[7]  
GODDEN J, 1992, ANTICANCER RES, V12, P1683
[8]   Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia [J].
Hurvitz, JR ;
Suwairi, WM ;
Van Hul, W ;
El-Shanti, H ;
Superti-Furga, A ;
Roudier, J ;
Holderbaum, D ;
Pauli, RM ;
Herd, JK ;
Van Hul, E ;
Rezai-Delui, H ;
Legius, E ;
Le Merrer, M ;
Al-Alami, J ;
Bahabri, SA ;
Warman, ML .
NATURE GENETICS, 1999, 23 (01) :94-98
[9]   IRS-1 expression and activation are not sufficient to activate downstream pathways and enable IGF-I growth response in estrogen receptor negative breast cancer cells [J].
Jackson, JG ;
Yee, D .
GROWTH HORMONE & IGF RESEARCH, 1999, 9 (05) :280-289
[10]   Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells [J].
Jackson, JG ;
White, MF ;
Yee, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) :9994-10003